Related Experiment Video

Updated: May 16, 2026

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)

Published on: May 16, 2012

miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways

Shahana Majid1, Altaf A Dar, Sharanjot Saini

  • 1Department of Urology, VA Medical Center and UCSF, San Francisco, CA 94121, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|November 14, 2012
PubMed
Abstract

Insights

MicroRNA-34b (miR-34b) acts as a tumor suppressor in prostate cancer, being silenced by hypermethylation. Restoring miR-34b inhibits cancer growth and improves survival.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • MicroRNAs (miRNAs) play dual roles as oncomirs or tumor suppressors in cancer.
  • The specific role of miR-34b in prostate cancer (PCa) requires further investigation.

Purpose of the Study:

  • To investigate the expression status and functional role of miR-34b in prostate cancer.
  • To elucidate the mechanisms underlying miR-34b regulation and its impact on PCa progression.

Main Methods:

  • Quantitative real-time PCR and in situ hybridization for miR-34b profiling in PCa cell lines and tissues.
  • In vitro and in vivo experiments to assess biological significance.
  • Statistical analyses for diagnostic and prognostic potential evaluation.

Main Results:

  • miR-34b is silenced in PCa via CpG hypermethylation, forming a feedback loop with methyltransferases.
  • Restored miR-34b expression predicts better survival, inhibits proliferation, migration, invasion, and induces cell-cycle arrest and apoptosis.
  • miR-34b suppresses epithelial-to-mesenchymal transition and demonstrates in vivo antitumor effects.

Conclusions:

  • miR-34b functions as a tumor suppressor in prostate cancer by targeting epigenetic regulators and Akt pathways.
  • Findings suggest miR-34b as a potential therapeutic target for epigenetic-based prostate cancer treatment.

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...